GUANGZHOU, China, Aug. 27 /Xinhua-PRNewswire-FirstCall/ -- China Medicine Corporation (“CMC”) , a leading distributor of prescription and over the counter pharmaceutical products, traditional Chinese medicines, Chinese herbs, nutritional supplements, dietary supplements, medical supplies and medical formulations, today announced that management will present at the Roth Capital Partners New York Conference, which will be held on September 5th and 6th at the Westin Hotel, located at Times Square in New York, New York.
Mr. Senshan Yang, CEO of China Medicine, will present on Thursday, September 6th at 9:00 a.m. in Track 7 (The Ambassador II Room), with a break- out period immediately following. Mr. Yang will provide investors with a corporate overview, including a discussion of the Company’s products, its production capabilities, the evolution and drivers of the Chinese pharmaceutical market, in addition to providing a summary of recent financial results and future growth initiatives.
Participation is by invitation only or through your Roth Capital representative. Investor meetings are available for confirmed guests, can be booked through your representative and management will be available the entire day of Thursday, September 6 to participate. Information on the Roth New York Conference can be found at http://www.roth.com.
About China Medicine Corporation
China Medicine is a distributor of prescription and over the counter pharmaceutical products, traditional Chinese medicines (finished medicines made of Chinese herbs), Chinese herbs, nutritional supplements, dietary supplements, medical supplies and medical formulations to over 28 provinces and 800 customers within China. The Company sells more than 2,200 products and is actively building a pipeline of proprietary traditional and Chinese herbal remedy products targeting oncology, high blood pressure and the removal of Aflatoxins from food and animal feed. For more information visit the Company’s website at http://www.chinamedicinecorp.com.
Safe Harbor Statement
This presentation may contain forward-looking statements concerning China Medicine Corp. The actual results may differ materially depending on a number of risk factors and all forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and all risk factors detailed in the Company’s reports filed with the Securities and Exchange Commission.
For more information, please contact: China Medicine Corporation Mary Xia Phone: +86-732-438-8866 Email: mary66882002@yahoo.com Investors: Matt Hayden, Hayden Communications Phone: +1-858-704-5065 Email: matt@haydenir.com
China Medicine Corporation
CONTACT: Mary Xia of China Medicine Corporation at +86-732-438-8866, ormary66882002@yahoo.com; Investors should contact Matt Hayden of HaydenCommunications at +1-858-704-5065, or matt@haydenir.com
